Behind The NASH Leaders, Pursuers Already Anticipating Second-Wave Improvements
Executive Summary
Privately held Cirius and NGM and big pharma Bristol-Myers Squibb are in Phase II for NASH with programs also working to validate non-invasive biomarkers for diagnosis, prognosis and treatment impact.
You may also be interested in...
Deal Watch: Celgene Joins Line Of Partners Tapping Exscientia’s AI-Driven Discovery Engine
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
AstraZeneca's License Of Ionis NASH Candidate Illustrates Still Hot Competition
Along with last week's acquisition of three NASH candidates from Lilly by Terns, NASH remains a heavily crowded R&D space as the European Association for the Study of the Liver annual meeting approaches.
Cirius CEO Bob Baltera On Being In Hot Pursuit Of NASH
In a video interview at the Biotech Showcase, Cirius CEO Bob Baltera explains his company's approach to NASH and looks forward to milestones ahead for its insulin-sensitizing lead candidate MSDC-0602K.